Simple blood test could replace risky prenatal procedures for down syndrome

NCT ID NCT01118507

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new blood test that looks at fetal DNA in the mother's blood to detect Down syndrome (trisomy 21) as early as the first trimester. Researchers enrolled 976 pregnant women at high risk and compared the blood test results to standard invasive methods. The goal was to see if this noninvasive approach could accurately identify affected pregnancies, potentially offering a safer alternative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this could provide a safe, noninvasive way to detect Down syndrome early in pregnancy, reducing the need for risky invasive tests.

What could go wrong

The test is still being validated and may not be as accurate as traditional methods. It also requires further study before widespread use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRISOMY 21 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

translocation Down syndrome trisomy 21

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chi Poissy St Germain

    Poissy, 78300, France

  • Necker Enfants Malades

    Paris, 75015, France